Akari Therapeutics, Plc Gains 42.02%
Tue, Jul 07, 2026 at 07:46 PM
Akari Therapeutics, Plc (AKTX:NASDAQ) soared at $15.48, a gain of 42%. On Tue, Jul 07, 2026, AKTX:NASDAQ touched a New 2-Week High of $15.48. The stock appeared on our News Catalysts scanner on Tue, Jul 07, 2026 at 12:16 PM in the 'MISCELLANEOUS' category. From Tue, Jun 23, 2026, the stock recorded 66.67% Up Days and 50.00% Green Days
The stock spiked on Thu, May 28, 2026 at $29.32 with a volume of 1M+.
About Akari Therapeutics, Plc (AKTX:NASDAQ)
Akari Therapeutics PLC is a biopharmaceutical company in clinical stage. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system.
Top 10 Gainers:
- SRAX, Inc. (SRAX:NASDAQ), 287.5%
- Crinetics Pharmaceuticals, Inc. (CRNX:NASDAQ), 98.74%
- ClearOne, Inc. (CLRO:NASDAQ), 97.71%
- Tvardi Therapeutics, Inc. (TVRD:NASDAQ), 54.23%
- The Beauty Health Company (SKIN:NASDAQ), 47.04%
- Akari Therapeutics, Plc (AKTX:NASDAQ), 42.02%
- Sky Quarry Inc. (SKYQ:NASDAQ), 41.51%
- Trident Digital Tech Holdings Ltd (TDTH:NASDAQ), 40.66%
- Veraxa Biotech AG (VRXA:NASDAQ), 38.36%
- Turn Therapeutics Inc. (TTRX:NASDAQ), 26.27%